lung cancer non-small cell lung carcinoma
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adult patients (age 18 years and over) with: -Newly diagnosed or suspected NSCLC stage IB, IIB or limited stage III (T3N1) (at least 30mm in smallest diameter); -Primary surgical resection (wedge excision, segmentectomy, lobectomy or pneumonectomy).
Exclusion criteria
Exclusion criteria: - Neoadjuvant treatment prior to surgery; - No staging CT or FDG-PET available; - Contra-indication for surgery: o Based on (biological) age, cardiovascular risk factors, expected remaining lung function, performance status or other co-morbidity as decided by a multidisciplinary team including medical oncologists, thorax surgeons, pulmonologists, radiation oncologists, pathologists, radiologists and nuclear medicine physicians. - Contra-indication for dynamic FDG-PET: o Diabetes mellitus; o Pregnancy; o Breast-feeding; o Severe claustrophobia. o Post-obstruction pneumonia (false-positive FDG-PET) - Interval between staging CT/FDG-PET, dynamic FDG-PET and surgery more than 28 days; - Histology proven non-NSCLC or high suspicion for tumour of other origin (e.g. metastasis of colorectal, breast or pharyngeal origin); - Inability to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biological and dimensional correlation between FDG-PET, CT and surgical derived specimens. These parameters will be used in prediction models for patient survival. | — |
Secondary
| Measure | Time frame |
|---|---|
| Use the most accurate technique found in (dynamic) FDG-PET tumour delineation for analysis of tumour activity, blood fraction, heterogeneity and full kinetic parameters and to correlate these with both histological findings (2A) and patient prognosis (2B) to come to in vivo predictive biological parameters. | — |
Countries
Netherlands
Outcome results
None listed